针对未满足医疗需求的抗菌药物灵活开发计划
美国食品药品监督管理局(FDA)认识到,对于有效疗法有限或缺乏的耐药病原体所致严重细菌性疾病,抗菌药物存在未满足的医疗需求。该机构还认识到,设计并开展评估耐药感染治疗药物安全性和有效性的临床试验具有挑战性,尤其是对于仅对单一或少数细菌菌种有活性的药物,因此更灵活的开发计划可能是合适的。本文讨论了针对旨在满足未满足医疗需求的抗菌药物灵活开发计划的若干监管考虑因素,并以最近批准注射用舒巴坦和注射用度洛巴坦(XACDURO)用于治疗由鲍曼不动杆菌-醋酸钙不动杆菌复合体敏感分离株所致的医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎为例。
要点
- FDA认识到耐药病原体所致严重细菌感染存在未满足医疗需求。
- 针对仅对单一或少数菌种有活性的抗菌药物,临床试验设计具有挑战性。
- 更灵活的抗菌药物开发计划可能是合适的。
核心结论
- 对于旨在满足未满足医疗需求的抗菌药物,更灵活的开发计划可能是合适的。
研究设计与样本
- 本文讨论针对抗菌药物灵活开发计划的若干监管考虑因素,并以注射用舒巴坦和注射用度洛巴坦(XACDURO)的近期批准为例。
主要发现
- FDA认识到,对于有效疗法有限或缺乏的耐药病原体所致严重细菌性疾病,抗菌药物存在未满足的医疗需求。
- FDA认识到,设计并开展评估耐药感染治疗药物安全性和有效性的临床试验具有挑战性,尤其是对于仅对单一或少数细菌菌种有活性的药物。
关键数值与推荐
- 注射用舒巴坦和注射用度洛巴坦(XACDURO)用于治疗由鲍曼不动杆菌-醋酸钙不动杆菌复合体敏感分离株所致的医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking. The agency also recognizes that designing and conducting clinical trials to assess the safety and efficacy of drugs to treat resistant infections is challenging, especially for drugs only active against a single or a few bacterial species, and that a more flexible development program might be appropriate. In this article, we discuss several regulatory considerations for flexible development programs for antibacterial drugs intended to meet an unmet medical need. As an example, we use the recent approval of sulbactam for injection and durlobactam for injection (XACDURO) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
引用
- Ghosh M, Iarikov D, Qi XK, et al. Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs. Emerg Infect Dis. 2024. PMID: 39447134. doi:10.3201/eid3011.231416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。